Dimitrios Kontoyiannis, MD
Infectious Disease · Houston, TXNPI 1649376476
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,654 of the $40,756 with a category attached, or 75.2%. 7 manufacturers reported payments, led by Merck at 31.2% of the total. Reporting peaked in 2021 at $16,530 and has fallen 90.3% since, to $1,601 in 2024. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $1235.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$13K
- Gilead$12K
- Cidara Therapeutics, Inc.$7K
- Astellas Pharma US Inc$3K
- AbbVie$3K
- Mayne Pharma Commercial LLC$2K
- plus $1K from 1 others
Across 39 payments — averaging $17,359 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$467K
- Gilead$200K
- AbbVie$10K
- Astellas US Technologies$566
What the payments were for
- Consulting fees$30,65475%
- Speaking & faculty fees$8,54521%
- Travel & lodging$1,3743%
- Food & beverage$1830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 12 | $12,697 |
| Gilead | 4 | $12,150 |
| Cidara Therapeutics, Inc. | 3 | $6,800 |
| Astellas Pharma US Inc | 8 | $2,817 |
| AbbVie | 2 | $2,813 |
| Mayne Pharma Commercial LLC | 3 | $2,080 |
| Pfizer | 1 | $1,400 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,756 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 11 | $36,589 |
| Daptomycin | 14 | $22,757 |
| Cefepime Hcl | 13 | $2,493 |
| Fluconazole | 17 | $560 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $216 |
| Azithromycin | 21 | $157 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.